双歧杆菌和乳杆菌在诱发抗肿瘤免疫中的作用

双歧杆菌和乳杆菌给封闭群昆明小鼠腹腔注射,在体内激活后,胸腺细胞和脾细胞对ＣｏｎＡ刺激的增殖反应,脾贴附性细胞对ＹＡＣ－１,Ｌ９２９的细胞毒作用,以及脾贴附性细胞产生对上述二株瘤细胞的肿瘤坏死因子（ＴＮＦ）的活性都比对照动物明显增强。结果提示短双歧杆菌和嗜酸性乳杆菌给小鼠腹腔注射后,通过激活脾脏淋巴细胞和贴附性细胞（巨噬细胞）所介导的免疫功能而明显地增强宿主的抗肿瘤活性。     

植物乳杆菌ZDY2013与两歧双歧杆菌WBIN03对TNBS诱导小鼠结肠炎的缓解作用

目的为阐明益生菌抗氧化与结肠炎的关系,对植物乳杆菌ZDY2013与两歧双歧杆菌WBIN03缓解三硝基苯磺酸(trinitro-benzene-sulfonic acid,TNBS)诱导的小鼠结肠炎进行探究。方法通过对BALB/c小鼠肛门注射TNBS,构建小鼠结肠炎模型;分别采用植物乳杆菌ZDY2013与两歧双歧杆菌WBIN03的单菌悬液(10~9CFU/mL)及1:1混合菌悬液(10~9CFU/mL)进行8 d灌胃治疗。结果治疗组小鼠结肠组织炎性细胞浸润症状获得缓解,血清中谷胱甘肽过氧化物酶(glutathione peroxidase,GSH-PX)(t_1=3.247,P_10.05;t_2=3.397,P_20.05)、过氧化氢酶(catalase,CAT)(t_1=5.289,P10.001;t_2=3.563,P_20.05)和总超氧化物歧化酶(total superoxide dismutase,T-SOD)(t_1=3.317,P_10.05;t_2=3.551,P_20.05)活性均有显著恢复。结论植物乳杆菌ZDY2013与两歧双歧杆菌WBIN03可通过增强机体抗氧化酶活性,起到缓解TNBS诱导的小鼠结肠炎的作用。     

双歧杆菌及其表面分子的免疫增强作用

研究双歧杆菌及其脂磷壁酸、细胞壁肽聚糖、培养乏液对小鼠腹腔渗出细胞、脾细胞ＩＬ－１、ＩＬ－２、ＩＬ－６、ＴＮＦ、ＩＦＮ－γ活性和脾ＮＫ、ＬＡＫ细胞活性的影响。结果发现双歧杆菌全菌、脂磷壁酸、肽聚糖多次注入小鼠腹腔一段时间后,小鼠脾ＮＫ细胞、ＬＡＫ细胞活性和ＩＦＮ－γ活性增强,腹腔渗出细胞产生ＩＬ－１、ＩＬ－６、ＴＮＦ活性增强,其中以脂磷壁酸作用最强,肽聚糖次之,培养乏液也有一定作用。双歧杆菌及其表面分子对小鼠脾细胞、腹腔渗出细胞ＩＬ－２活性无显著影响。双歧杆菌的免疫增强作用在抗感染、抗肿瘤机理中占有十分重要的地位。     

双歧杆菌总DNA对小鼠IL-2、NK活性影响的研究

目的　从双歧杆菌、大肠杆菌提取 DNA,用 DNA免疫小鼠 ,观察免疫功能的变化 ,探讨双歧杆菌 DNA对小鼠免疫功能的影响 ,并作对比研究。方法　肌肉注射提取的双歧杆菌 DNA、大肠杆菌 DNA,颈椎处死后 ,检测脾细胞的免疫功能 ,同时提取 IEL细胞与 DNA共孵育 ,检测它对 IEL细胞的激活情况及细胞因子产生情况 ,以自然杀伤细胞 (NK)活性 ,白细胞介素 2 (IL - 2 )产生能力为指标 ,测定小鼠上述各项指标变化。结果　双歧杆菌 DNA、大肠杆菌 DNA肌肉注射后 ,小鼠以上两项指标与相应对照组相比较均明显提高 (P<0 .0 5 )。双歧杆菌 DNA提高小鼠 NK活性与 IL - 2水平程度大于大肠杆菌 DNA的作用(P<0 .0 1)。结论　双歧杆菌 DNA可快速激活 NK活性 ,提高体内 IL - 2水平。其效能优于大肠杆菌DNA。     

青春型双歧杆菌生态制品对小鼠肝癌抑制作用的初步研究

本文观察了青春型双歧杆菌(Bif.a)对小鼠肝癌移植瘤的抑制作用。结果发现,青春型双歧杆菌在瘤细胞移植前或移植后应用均显示了抑制肿瘤生长的作用。将青春型双歧杆菌注入肤腔可激活肤腔巨噬细胞,提高其吞噬功能和非特异性酯酶活性,而加入体外培养的小鼠肝癌细胞未显示有杀伤瘤细胞作用。认为青春型双歧杆菌的抑瘤作用可能是该菌刺激了宿主的免疫活性细胞杀伤了瘤细胞,而非直接杀伤作用。     

双歧杆菌及中药对小鼠血中抗氧化酶,T3,TSH和吞噬细胞功能的影响

本文用双歧杆菌、中药及复方双歧杆菌制剂饲喂ＢＡＬＢ／ｃ小鼠,发现中药及复方双歧杆菌制剂对老龄鼠血中ＳＯＤ、ＧＳＨ—Ｐｘ活性有明显增高作用,而对ＬＰＯ含量有明显减低作用,双歧杆菌及复方双歧杆菌能增强ＢＡＬＢ／ｃ小鼠内分泌功能及免疫功能,本试验中尚发现双歧杆菌与中药制成的复方双歧杆菌制剂能明显协同促进ＧＳＨ—Ｐｘ及吞噬细胞功能。说明双歧杆菌与一些传统补益类中药具有协同抗衰老作用。     

阿莫西林干预对婴儿优势菌在无菌小鼠体内定植的影响

目的考察阿莫西林干预对婴儿优势菌双歧杆菌及乳杆菌在无菌小鼠体内定植的影响。方法 1日龄Balb/c无菌乳鼠接种婴儿粪便悬液。饲养至7~21日龄灌胃阿莫西林(100mg/kg),对照组在同日龄给予等体积的生理盐水。利用qRT-PCR检测小鼠粪便中双歧杆菌、乳杆菌的含量。结果阿莫西林处理可显著降低乳杆菌(P0.05)、双歧杆菌(P0.05)在无菌小鼠体内定植数量,但停药后饲养至成年(53日龄)二者定植数量与对照组小鼠比较差异无统计学意义(P0.05)。结论哺乳期阿莫西林干预会导致乳杆菌、双歧杆菌在小鼠体内定植量下降,但停药后小鼠饲养至成年二者可达到正常定植量,婴儿菌群定植小鼠模型可以模拟与现有动物模型一致的阿莫西林对双歧杆菌、乳杆菌定植的影响规律。     

双歧杆菌脂磷壁酸对B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响

目的探讨双歧杆菌脂磷壁酸（LTA）对黑色素瘤B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响。方法将黑色素瘤B16细胞接种于C57BL／6小鼠皮下,待触及肿块后于荷瘤小鼠皮下注射双歧杆菌LTA。采用MTT、流式细胞术（FCM）、RT-PCR方法分别检测经双歧杆菌LTA处理后B16荷瘤小鼠NK细胞杀伤活性、NK细胞NKG2D受体蛋白表达以及肿瘤组织内Rae-1、H60 mRNA表达的变化。结果与对照组相比,经双歧杆菌LTA处理后,B16荷瘤小鼠的NK细胞杀伤活性增强（P〈0．05）,NK细胞受体NKG2D表达明显增加（P〈0．05）,肿瘤组织Rae-1、H60 mRNA表达上升（P〈0．05）,并具有浓度依赖性。结论双歧杆菌LTA能够增强B16荷瘤小鼠NK细胞的杀伤活性,其机制可能与上调NK细胞受体NKG2D的蛋白表达和肿瘤组织Rae-1、H60 mRNA的表达有关。     

双歧杆菌脂磷壁酸对化疗荷瘤小鼠免疫功能的影响

目的探讨双歧杆菌脂磷壁酸对5-氟尿嘧啶（5-FU）化疗肝癌H22荷瘤小鼠免疫的影响及其作用机制。方法双歧杆菌脂磷壁酸处理5-Fu化疗的H纶荷瘤Balb／c小鼠,MTT法检测NK细胞和CTL细胞杀伤活性;采用流式细胞仪检测荷瘤小鼠脾细胞中T亚群比例;用RT-PCR和Western Not方法分别检测荷瘤小鼠肿瘤组织Foxp3和TIM-3mRNA及蛋白的表达变化。结果荷瘤小鼠脾细胞中CD4^＋ CD25^＋Tmg比例高,并存在Foxp3和TIM-3 mRNA及蛋白的高表达,经双歧杆菌LTA和5．Fu处理后CD4^＋CD25^＋Tmg比例下降,Foxp3和TIM-3mRNA及蛋白表达水平也均呈下调趋势,但5-FU单独处理后的荷瘤小鼠脾细胞中CD4^＋细胞比例也减少,NK细胞和CTL杀伤率均降低,而双歧杆菌LTA处理后CD4^＋细胞比例,NK细胞和CTL杀伤率却明显增加。二者联合处理也能增加CD^＋细胞比例及NK细胞和CTL杀伤率。结论双歧杆菌脂磷壁酸联合5-FU可通过增强NK细胞和CTL杀伤能力,同时抑制TIM-3／TIM-3L途径,降低CD4^＋CD25^＋Tmg的免疫抑制活性,增强机体细胞免疫来提高化疗抗肿瘤效果,减轻化疗副作用,增强宿主对化疗的耐受性,从而提高抗肿瘤作用。     

双歧杆菌总DNA对小鼠IL—2,NK活性影响的研究

目的 从双歧杆菌、大肠杆菌提取ＤＮＡ,用ＤＮＡ免疫小鼠,观察免疫功能的变化,探讨双歧杆菌ＤＮＡ对小鼠免疫功能的影响,并作对比研究。方法 肌肉注射提取的双歧杆菌ＤＮＡ、大肠杆菌ＤＮＡ,颈椎处死后,检测脾细胞的免疫功能,同时提取ＩＥＬ细胞与ＤＮＡ共孵育,检测它对ＩＥＬ细胞的激活情况及细胞因子产生情况,以自然杀伤细胞（ＮＫ）活性,白细胞介素２（ＩＬ－２）产生能力为指标,测定小鼠上述各项指标变化。结果 双歧杆菌ＤＮＡ、大肠杆菌ＤＮＡ肌肉注射后,小鼠以上两项指标与相应对照组相比较均明显提高（Ｐ〈０．０５）。双歧杆菌ＤＮＡ提高小鼠ＮＫ活性与ＩＬ－２水平程度大于大肠杆菌ＤＮＡ的作用（Ｐ〈０．０１）。结论 双歧杆菌ＤＮＡ可快速激活ＮＫ活性,提高体内ＩＬ－２水平。其效能优于大肠杆菌ＤＮＡ。     

Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis

A new vaccination strategy is urgently needed for improved control of the global tuberculosis (TB) epidemic. Using a mouse aerosol Mycobacterium tuberculosis challenge model, we investigated the protective efficacy of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG (ΔmmaA4BCG) formulated in dimethyl dioctadecyl ammonium bromide (DDA) - D(+) trehalose 6,6 dibenenate (TDB) (DDA/TDB) adjuvant. In previous studies, deletion of the mmaA4 gene was shown to reduce the suppression of IL-12 production often seen after mycobacterial infections. While the non-adjuvanted ΔmmaA4BCG strain did not protect mice substantially better than conventional BCG against a tuberculous challenge in four protection experiments, the protective responses induced by the ΔmmaA4BCG vaccine formulated in DDA/TDB adjuvant was consistently increased relative to nonadjuvanted BCG controls. Furthermore, the ΔmmaA4BCG-DDA/TDB vaccine induced significantly higher frequencies of multifunctional (MFT) CD4 T cells expressing both IFNγ and TNFα (double positive) or IFNγ, TNFα and IL-2 (triple positive) than CD4 T cells derived from mice vaccinated with BCG. These MFT cells were characterized by having higher IFNγ and TNFα median fluorescence intensity (MFI) values than monofunctional CD4 T cells. Interestingly, both BCG/adjuvant and ΔmmaA4BCG/adjuvant formulations induced significantly higher frequencies of CD4 T cells expressing TNFα and IL-2 than nonadjuvanted BCG or ΔmmaA4BCG vaccines indicating that BCG/adjuvant mixtures may be more effective at inducing central memory T cells. Importantly, when either conventional BCG or the mutant were formulated in adjuvant and administered to SCID mice or immunocompromised mice depleted of IFNγ, significantly lower vaccine-derived mycobacterial CFU were detected relative to immunodeficient mice injected with non-adjuvanted BCG. Overall, these data suggest that immunization with the ΔmmaA4BCG/adjuvant formulation may be an effective, safe, and relatively inexpensive alternative to vaccination with conventional BCG.     

Overexpression of IL-15 in vivo enhances protection against Mycobacterium bovis bacillus Calmette-Guérin infection via augmentation of NK and T cytotoxic 1 responses.

To investigate the immunomodulating effects of IL-15 in vivo on mycobacterial infection, we used IL-15-transgenic (Tg) mice, which were recently constructed with cDNA-encoding secretable isoform of IL-15 precursor protein under the control of a MHC class I promoter. The IL-15-Tg mice exhibited resistance against infection with Mycobacterium bovis bacillus Calmette-Guérin (BCG), as assessed by bacteria growth. IFN-gamma level in serum was significantly higher in IL-15-Tg mice than in non-Tg mice after BCG infection. NK cells were remarkably increased, and Ag-specific T cytotoxic 1 response mediated by CD8+ T cells producing IFN-gamma was significantly augmented in the IL-15-Tg mice following BCG infection. Neutralization of endogenous IFN-gamma by in vivo administration of anti-IFN-gamma mAb deteriorated the clearance of the bacteria. Depletion of of NK cells or CD8+ T cells by in vivo administration of anti-asialo-GM(1) Ab or anti-CD8 mAb hampered the exclusion of bacteria. Thus, overexpression of IL-15 in vivo enhanced protection against BCG infection via augmentation of NK and T cytotoxic 1 responses.     

A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection

A CD30 ligand (CD30L, CD153) is a type II membrane-associated glycoprotein belonging to the TNF family. To illustrate the potential role of CD30L in CD4(+) Th1 cell responses, we investigated the fate of Ag-specific CD4(+) T cells in CD30L-deficient (CD30L(-/-)) mice after Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. The number of bacteria was significantly higher in organs of CD30L(-/-) mice than in wild-type (WT) mice 4 wk postinfection. The numbers of purified protein derivative- or Ag85B-specific-IFN-gamma-producing-CD4(+) T cells in spleen, lung, or peritoneal exudate cells were significantly fewer in CD30L(-/-) mice than in WT mice. During the infection, CD30L was expressed mainly by CD44(+)CD3(+)CD4(+) T cells but not by CD3(+)CD8(+) T cells, B cells, dendritic cells, or macrophages. Costimulation with agonistic anti-CD30 mAb or coculturing with CD30L-transfected P815 cells restored IFN-gamma production by CD4(+) T cells from BCG-infected CD30L(-/-) mice. Coculturing with CD30L(+/+)CD4(+) T cells from BCG-infected WT mice also restored the number of IFN-gamma(+)CD30L(-/-)CD4(+) T cells. When transferred into the CD30L(+/+) mice, Ag-specific donor CD30L(-/-) CD4(+) T cells capable of producing IFN-gamma were restored to the compared level seen in CD30L(+/+) CD4(+) T cells on day 10 after BCG infection. When naive CD30L(+/+) T cells were transferred into CD30L(-/-) mice, IFN-gamma-producing-CD4(+) Th1 cells of donor origin were normally generated following BCG infection, and IFN-gamma-producing-CD30L(-/-)CD4(+) Th1 cells of host origin were partly restored. These results suggest that CD30L/CD30 signaling executed by CD30(+) T-CD30L(+) T cell interaction partly play a critical role in augmentation of Th1 response capable of producing IFN-gamma against BCG infection.     

Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guèrin)BCG monoclonal antibody

Summary The anti-idiotypic antibody (Ab2) prepared against the anti-BCG monoclonal antibody (mAb) (Ab1) exhibited potential vaccine activity against Meth A fibrosarcoma that shared a common antigen(s) withMycobacterium bovis strain bacillus Calmette Guèrin (BCG). Mice vaccinated with the anti-idiotypic antibody (Ab2) were protected significantly against growth of the transplanted Meth A tumor (66%), and the presence of anti-(anti-idiotypic antibody) (Ab3) was proved in the Ab2-vaccinated mice by enzyme-linked immunosorbent assay and indirect immunofluorescence analyses using unabsorbed or absorbed sera against the BCG antigen(s) and Meth A tumor cells. This indicated that the anti-idiotypic antibody (Ab2) mimicked the structures of the BCG antigen(s) and behaved as the BCG antigen(s) to induce the Abl-like antibody (Ab3) in vivo. Presumably the Ab2-induced Ab3 plays a significant role in preventing growth of the transplanted tumor in animals. By contrast, the control mice treated with normal mouse serum failed to inhibit the tumor growth. These results suggest the possible development of a tumor vaccine from the anti-idiotypic antibody (Ab2) prepared against the anti-BCG monoclonal antibody, for tumors sharing a common antigen(s) withMycobacterium bovis strain BCG.

---

Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guèrin)BCG monoclonal antibody

     

Studies on the recovery from tolerance to tumor antigens

C3H/He mice were injected i.v. with heavily X-irradiated syngeneic X5563 tumor cells three times at 4-day intervals. This regimen resulted in the abrogation of the potential to generate X5563 tumor-specific T cell-mediated immunity as induced by i.d. inoculation of viable X5563 tumor cells followed by surgical resection of the tumor, representing the tolerance induction. Although such a tumor-specific tolerant state was long-lasting, the recovery of anti-X5563 effector T cell responses was observed when the above ordinary immunization procedure was performed 6 months after the tolerance induction. The present study investigated whether the recovery from the tolerance can be accelerated by applying a helper-effector T-T cell interaction model in which enhanced anti-X5563 immunity is obtained by priming mice with BCG and by immunizing X5563 tumor cells modified with BCG cross-reactive MDP hapten (designated as L4-MDP) in the presence of anti-L4-MDP helper T cells preinduced with BCG. The results demonstrated that BCG-primed mice which received the tolerance regimen failed to generate anti-X5563 immunity when the ordinary immunization was performed 2 or 3 months after the tolerance induction. In contrast, the immunization of BCG-primed and X5563-tolerant mice with L4-MDP-coupled X5563 tumor cells at comparable timing to that of the ordinary immunization were capable of generating potent X5563-specific in vivo protective T cell-mediated immunity. As control groups, BCG-primed or unprimed tolerant mice did not develop anti-X5563 immunity when immunized with L4-MDP-uncoupled or L4-MDP-coupled tumor cells, respectively. These results indicate that immunization of BCG-primed, tumor-tolerant mice with L4-MDP-modified tumor cells results in accelerated recovery from the tumor tolerance.     

Differential effects of two probiotic strains with different bacteriological properties on intestinal gene expression, with special reference to indigenous bacteria

Probiotics are used for the improvement of gut disorders. To explore the potential of probiotics, a gnotobiotic study using BALB/c mice to analyze epithelial gene expression was performed. Microarray analysis of probiotic strain-monoassociated mice showed that Lactobacillus casei Shirota and Bifidobacterium breve Yakult noticeably affected gene expression in the ileal and colonic epithelial cells, respectively, although to a smaller extent than segmented filamentous bacteria (SFB). Lactobacillus casei Shirota enhanced the gene expression involving defense/immune functions and lipid metabolism more strongly than B. breve Yakult. In the colon, expression of a chloride transporter was slightly enhanced, although downregulation of many genes, such as guanine nucleotide-binding protein, was evident in mice with B. breve Yakult compared with the ones with L. casei Shirota. SFB affected gene expression more strongly than the probiotic strains. In particular, alpha(1-2) fucosyltransferase and pancreatitis-associated protein were significantly enhanced only in SFB-monoassociated mice but not probiotic strain-monoassociated mice. Gene expression of SFB-monoassociated mice was either stimulated or repressed in a manner similar to or opposite that of conventional colonized mice. Taken together, probiotic strains of L. casei Shirota and B. breve Yakult differentially affect epithelial gene expression in the small intestine and colon, respectively.     

The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide

Summary We determined whether the systemic administration of viable Mycobacterium bovis organisms (BCG) or a lipophilic derivative of muramyl tripeptide (MTP-PE) would lead to the activation of antitumor properties in murine Kupffer cells (KC). KC-mediated tumor cytolysis was determined by the release of radiolabeled nuclear breakdown products of target cells. KC harvested from either C57BL/6 or C3H/HEN mice treated with saline exhibited no cytotoxicity against syngeneic B16 melanoma or UV-2237 fibrosarcoma cells. In contrast, KC harvested from BCG or MTP-PE-injected mice were highly cytotoxic against the tumor targets, as measured by an in vitro radiorelease assay. The demonstration that the administration of macrophage activators can generate in situ tumoricidal activity in KC suggests that these cells can be important in the control of hepatic micrometastases.     

Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy

Bacillus Calmette Guerin (BCG) immunotherapy has anti-tumorigenic effects against bladder cancer. To improve the efficacy of BCG therapy, we introduced the gene encoding the 65 kDa heat shock protein (hsp) of Mycobacterium tuberculosis into a mouse malignant melanoma cell line (B16). An expression vector harboring the 65 kDa antigen gene was transfected into B16 using Lipofectamine, then expression of the antigen was confirmed by RT-PCR and Western blotting. Several cell lines expressing 65 kDa antigen were established (B16/65 kDa). We also established a control cell line transfected with the vector alone (B16/con). All cell lines (B16, B16/con, B16/65 kDa) were injected intraperitoneally into syngeneic mice with or without BCG prior immunization and the development of tumor ascites was examined. To analyze the mechanism of the anti-tumor effect, CD4 T cells or CD8 T cells were depleted in vivo by administering the corresponding monoclonal antibody. B16/65k Da expressed the 65 kDa hsp of M. tuberculosis. The tumor growth of B16/65 kDa was slightly retarded in naive mice, but significantly inhibited by BCG. The anti-tumor effect was totally abrogated in mice deficient in CD4 T cells, suggesting that CD4 T cells are involved in this process. The 65 kDa hsp of M. tuberculosis was expressed after gene transduction in a malignant melanoma cell line and significantly enhanced the anti-tumor effect of BCG immunotherapy. CD4 T cells play an important role in this anti-tumor effect.     

Antileishmanial activities of macrophages from C3H/HeN and C3H/HeJ mice treated with Mycobacterium bovis strain BCG

C3H/HeN and C3H/HeJ mice were infected ip with viable BCG, a macrophage-activating agent, and their peritoneal exudate macrophages exposed to Leishmania tropica amastigotes. Macrophages from BCG-infected C3H/HeN mice had both leishmanicidal activities described for lymphokine activation of C3H/HeN macrophages in vitro: increased resistance to L. tropica infection, followed by intracellular killing of the parasite. Macrophages from BCG-infected C3H/HeN mice were also activated to kill tumor cells in vitro. In contrast, macrophages from BCG-treated C3H/HeJ mice were not resistant to L. tropica infection, did not kill intracellular amastigotes over 72 hr in culture, and were not cytotoxic to tumor cells.